Kallyope

Kallyope is a private, clinical-stage biotech translating groundbreaking neuroscience into novel therapeutics for migraine and metabolic diseases. Its lead asset, elismetrep (K-304), is a first-in-class TRPM8 antagonist for migraine entering pivotal studies in 2026, supported by positive Phase 2b data. The company's proprietary Klarity™ platform identifies novel neural circuits, fueling a pipeline that includes a differentiated non-incretin metabolic candidate (K-554) and a discovery partnership with Novo Nordisk. With a seasoned leadership team and backing from top-tier life science investors, Kallyope aims to address large markets with significant unmet need.

Klarity™ platform: an integrated suite of technologies for identifying and validating novel neural circuits and drug targets, particularly within the gut-brain axis.

In migraine, elismetrep competes with established CGRP antagonists (e.g., from AbbVie, Lundbeck, Eli Lilly) and older drug classes, requiring clear differentiation in efficacy or tolerability. In metabolic disease, the landscape is dominated by incretin-based therapies (e.g., semaglutide from Novo Nordisk, tirzepatide from Eli Lilly); K-554's success hinges on demonstrating advantages over these highly effective but injectable drugs with side effect profiles.